SAN DIEGO--(BUSINESS WIRE)--Splash Pharmaceuticals, Inc. (“Splash”), a closely held private biopharmaceutical company that develops novel cancer therapies, announced the presentation of an abstract related to the clinical trial of SPL-108 in platinum-resistant ovarian cancer patients. The Phase I trial is being conducted at Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, and the abstract will be presented by its first author Dr. Eugenia Girda, a member of the Institute’s Gynecologic Oncology Program.
Presentation Details:
American Society of Clinical Oncology
(ASCO) 2018 Annual meeting in Chicago, IL.
Poster Discussion:
Monday June 4, 2018 from 1:15 p.m. – 4:45 p.m. (CDT)
An
Open-label Phase 1 Trial of the Safety and Efficacy of Daily
Subcutaneous SPL-108 Injections When Used in Combination with Paclitaxel
in Patients with Platinum-resistant, CD44+, Advanced Ovarian Epithelial
Cancer.
Poster Presentation: Abstract #TPS5608, Poster Board
#331a, Hall A
http://abstracts.asco.org/214/AbstView_214_216747.html
About Splash Pharmaceuticals
Splash is a privately held company that is developing novel cancer therapies with a goal to provide dramatic and durable responses in many solid tumors. Splash has developed a pipeline of novel agents that target CD44 with demonstrated anti-angiogenic and anti-metastatic activity as well as synergistic cytotoxicity with other chemotherapy agents. Splash is actively seeking Pharma partners to accelerate its novel clinical programs. For more information, please visit www.splashpharma.com.